Mykola Protopopov·Jan 25, 2025Fragmenstein — An Ugly Duckling or a Swan?Fragment-based drug discovery (FBDD) — is a standard strategy in modern early drug discovery, with crystallographic screening playing a…
Mykola Protopopov·Nov 29, 2024PharmacoNet: deep learning-guided pharmacophore modeling for ultra-large-scale virtual screeningThe concept of chemical spaces is becoming a central point in early-stage drug discovery. In this context, the development of novel…
Mykola Protopopov·Nov 16, 2024Open Data and Algorithms in AI-driven molecular informaticsIn recent years, significant growth has been seen in using artificial intelligence (AI) and deep learning in molecular informatics. AI…
Mykola Protopopov·Oct 25, 2024Why Data Will Drive Machine Learning Success?The use of AI helps discover the existence and prediction of many different molecular structures in drug development. Imagine if AI could…
Mykola Protopopov·Oct 14, 2024Protein Kinases as Drug Targets and Kinase Inhibitors Library in Accelerating Discovery and…Protein kinases are key enzymes in cellular signaling pathways that play crucial roles in cell growth, differentiation, and apoptosis. They…
Mykola Protopopov·Sep 24, 2024Predicting Ligand Binding via Invariant Molecular Structure AnalysisPrediction of how small molecules bind to protein pockets is important in drug development, but traditional methods are often inaccurate…
Mykola Protopopov·Sep 5, 2024FeatureDock: Protein-Ligand Docking Guided by Physicochemical Feature-Based Local Environment…In the realm of computational drug discovery, predicting the interaction between proteins and ligands remains a significant challenge…
Mykola Protopopov·Jul 29, 2024Computational screening combined with well-tempered metadynamics simulations identifies potential…Type-II transmembrane serine proteases (TMPRSS2) are multifunctional proteases implicated in various diseases, including viral infections…
Mykola Protopopov·Jul 7, 2024MolScore: a scoring, evaluation and benchmarking framework for generative models in de novo drug…Modern distribution-learning based generative models offer a powerful approach to de novo drug design, enabling the creation of novel…
Mykola Protopopov·Jun 23, 2024Structure-based virtual screening of vast chemical space as a starting point for drug discoveryVirtual screening has extended beyond the constraints of tangible molecules, it enables to search for leads among billions of easily…